Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Top Cited Papers
- 30 January 2016
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 44, 42-50
- https://doi.org/10.1016/j.ctrv.2016.01.003
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumoursEMBO Molecular Medicine, 2013
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatmentProceedings of the National Academy of Sciences, 2009
- Platinum neurotoxicity pharmacogeneticsMolecular Cancer Therapeutics, 2009
- Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapyPharmacogenetics and Genomics, 2008
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trialEuropean Journal Of Cancer, 1998